Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
FRG2B (FSHD region gene 2 family member B) encodes a paralog of the FRG2 gene and is predicted primarily to produce noncoding RNAs highly similar to FRG2A, contributing to chromatin structure and nucleolar organization rather than classical protein function[1][2][5]. FRG2B transcript is enriched in the nucleus and is associated with heterochromatin, with a nucleolar sub-compartment localization. FRG2B, together with its paralogs, is thought to contribute to nuclear architecture as a scaffold for heterochromatin interactions with nucleolar periphery and has been investigated in the context of neuromuscular disease, especially as part of a locus altered in facioscapulohumeral muscular dystrophy. There is no definitive evidence supporting its role as a traditional therapeutic target, nor is there evidence of direct drug interactions or use as a biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FSHD region gene 2 family member B (FRG2B).